Targeted and armed oncolytic adenovirus via chemoselective modification.

Targeted and armed oncolytic adenovirus via chemoselective modification.
复制标题

通过化学选择性修饰有靶向和武装溶瘤腺病毒。

DOI:
10.1016/j.bmcl.2011.05.039
复制
发表时间:
2011-09-01
影响因子:
2.7
通讯作者:
Carrico, Isaac S.
Carrico, Isaac S.
中科院分区:
医学4区
文献类型:
--
作者:
Banerjee, Partha S.;Zuniga, Edison S.;Ojima, Iwao;Carrico, Isaac S.

文献摘要

参考文献

被引文献

相似文献

溶瘤腺病毒(ADS)是一种新兴的治疗癌症的替代疗法,但临床试验尚未显示出足够的疗效。当溶瘤ADS与紫杉类药物联合使用时,观察到细胞毒性和病毒复制的协同增加。为了产生下一代溶瘤腺病毒,病毒粒子被物理连接到一个高效的紫杉类化合物SB-T-1214和一个叶酸靶向基序。结合是通过非规范单糖(O-GlcNAz)和氨基酸(高丙氨酸)的代谢结合实现的,这些氨基酸作为化学选择性修饰的位点。
Oncolytic adenoviruses (Ads) are an emerging alternative therapy for cancer; however, clinical trial have not yet demonstrated sufficient efficacy. When oncolytic Ads are used in combination with taxoids a synergistic increase in both cytotoxicity and viral replication is observed. In order to generate a next generation oncolytic adenovirus, virion were physically conjugated to a highly potent taxoid, SB-T-1214, and a folate targeting motif. Conjugation was enabled via the metabolic incorporation of non-canonical monosaccharides (O-GlcNAz) and amino acids (homopropargylglycine), which served as sites for chemoselective modification.
溶瘤单纯疱疹病毒载体和紫杉烷类药物协同作用,促进前列腺癌细胞的杀伤。
DOI: 10.1038/cgt.2009.10
发表时间: 2009-07
影响因子: 6.4
作者:
通讯作者: --
DOI: 10.1186/1476-4598-9-192
发表时间: 2010-07-14
期刊: Molecular cancer
影响因子: 37.3
作者:
Botchkina GI;Zuniga ES;Das M;Wang Y;Wang H;Zhu S;Savitt AG;Rowehl RA;Leyfman Y;Ju J;Shroyer K;Ojima I
通讯作者: Ojima I
DOI: 10.1038/gt.2010.121
发表时间: 2011-02-01
期刊: GENE THERAPY
影响因子: 5.1
作者:
Huang, B.;Sikorski, R.;Thorne, S. H.
通讯作者: Thorne, S. H.
DOI: 10.1021/bc050147l
发表时间: 2005-11-01
影响因子: 4.7
作者:
Sen Gupta, S;Kuzelka, J;Finn, MG
通讯作者: Finn, MG
DOI: 10.1158/0008-5472.can-07-6193
发表时间: 2008-05-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Nagano, Satoshi;Perentes, Jean Yannis;Boucher, Yves
通讯作者: Boucher, Yves